A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome
| Autor: | Kerrie Lemons Chitwood, Andrea Schneider, Randi J Hagerman, Laura Greiss Hess, Danh V. Nguyen, Susan M. Rivera, Jonathan Polussa, David R Hessl, Yanjun Chen, Sarah E. Fitzpatrick, Marwa Eldeeb, Kimberly N. Gaul |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male Pediatrics Outcome Assessment Placebo-controlled study Medical and Health Sciences law.invention 0302 clinical medicine Randomized controlled trial law Sertraline Outcome Assessment Health Care Developmental and Educational Psychology SSRI fragile X syndrome Child Pediatric treatment Mental Disorders Fragile X syndrome Psychiatry and Mental health Mental Health 6.1 Pharmaceuticals Child Preschool Serotonin Uptake Inhibitors Female Selective Serotonin Reuptake Inhibitors medicine.drug medicine.medical_specialty Intellectual and Developmental Disabilities (IDD) Clinical Trials and Supportive Activities autism Developmental & Child Psychology Placebo ASD Article 03 medical and health sciences Rare Diseases Double-Blind Method Clinical Research Behavioral and Social Science Post-hoc analysis medicine Humans Preschool Psychiatry Psychotropic Drugs business.industry Psychology and Cognitive Sciences Neurosciences Evaluation of treatments and therapeutic interventions medicine.disease Brain Disorders Health Care 030104 developmental biology Fragile X Syndrome Pediatrics Perinatology and Child Health Clinical Global Impression Observational study business 030217 neurology & neurosurgery |
| Zdroj: | Journal of developmental and behavioral pediatrics : JDBP, vol 37, iss 8 |
| ISSN: | 1536-7312 |
| Popis: | Objective Observational studies and anecdotal reports suggest that sertraline, a selective serotonin reuptake inhibitor, may improve language development in young children with fragile X syndrome (FXS). Methods The authors evaluated the efficacy of 6 months of treatment with low-dose sertraline in a randomized, double-blind, placebo-controlled trial in 52 children with FXS aged 2 to 6 years. Results Eighty-one subjects were screened for eligibility, and 57 were randomized to sertraline (27) or placebo (30). Two subjects from the sertraline arm and 3 from the placebo arm discontinued. Intent-to-treat analysis showed no difference from placebo on the primary outcomes: the Mullen Scales of Early Learning (MSEL) expressive language (EL) age equivalent and Clinical Global Impression Scale-Improvement. However, analyses of secondary measures showed significant improvements, particularly in motor and visual perceptual abilities and social participation. Sertraline was well tolerated, with no difference in side effects between sertraline and placebo groups. No serious adverse events occurred. Conclusion This randomized controlled trial of 6 months of sertraline treatment showed no primary benefit with respect to early EL development and global clinical improvement. However, in secondary exploratory analyses, there were significant improvements seen on motor and visual perceptual subtests, the cognitive T score sum on the MSEL, and on one measure of social participation on the Sensory Processing Measure-Preschool. Furthermore, post hoc analysis found significant improvement in early EL development as measured by the MSEL among children with autism spectrum disorder on sertraline. Treatment appears safe for this 6-month period in young children with FXS, but the authors do not know the long-term side effects of this treatment. These results warrant further studies of sertraline in young children with FXS using refined outcome measures as well as longer term follow-up studies to address long-term side effects of low-dose sertraline in early childhood. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|